Methods for preparing ropivacaine suspension injections and powder formulations, and the resulting ropivacaine suspension injections and powder formulations.

Through acid-base reaction and excipient treatment, ropivacaine suspension injection and powder formulation with stable particle size were prepared, which solved the problems of poor sustained-release effect and high production cost of existing ropivacaine injections, and achieved long-acting sustained release and stable blood drug concentration, which is convenient for clinical application.

CN114504552BActive Publication Date: 2026-11-10ZHEJIANG CUIZE PHARM TECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202111290521.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-02
Publication Date
2026-11-10
Estimated Expiration
2041-11-02

AI Technical Summary

Technical Problem

Existing local anesthetics such as ropivacaine injection have poor sustained-release effects, are costly and have complex production processes, making them difficult to industrialize. Furthermore, the particle size of existing formulations is unstable during long-term storage and use, affecting the safety and efficacy of the drugs.

Method used

Ropivacaine suspension injection and powder formulation were prepared by adjusting the pH to above 7.5 through an acid-base reaction in water, adding pharmaceutically acceptable excipients such as polysorbate 80 as a surfactant, treating the mixture under dispersion conditions, and then freeze-drying.

Benefits of technology

This method achieves particle size stability in ropivacaine suspension injections and powder formulations, ensuring long-term sustained-release effects, stable blood drug concentrations, facilitating clinical administration, and reducing production costs and equipment requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114504552B_ABST
    Figure CN114504552B_ABST
Patent Text Reader

Abstract

This disclosure relates to a method for preparing a ropivacaine suspension for injection and the ropivacaine suspension for injection obtained by the method according to this disclosure. This disclosure also relates to the use of polysorbate 80 as a surfactant in the method for preparing the ropivacaine suspension for injection. This disclosure further relates to a method for preparing a ropivacaine powder formulation and the ropivacaine powder formulation obtained by the method according to this disclosure. This disclosure also relates to the use of polysorbate 80 as a surfactant in the method for preparing the ropivacaine powder formulation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to a method for preparing ropivacaine suspension injection and powder formulation, and the ropivacaine suspension injection and powder formulation obtained therefrom. Background Technology

[0002] Postoperative pain is acute pain that occurs immediately after surgery (usually lasting no more than 7 days). It is acute, nociceptive pain and is the most common and urgent type of acute pain in clinical practice. If not adequately controlled initially, it can easily develop into chronic postoperative pain. Opioids are commonly used clinically to treat postoperative pain, but they have adverse effects such as respiratory depression and addiction. Local anesthetics are also the most important analgesics in clinical practice, including procaine, lidocaine, tetracaine, bupivacaine, and ropivacaine. However, the effective duration of existing local anesthetics is relatively short (usually lasting less than 7 hours). Therefore, continuous incision analgesia devices are used clinically to infuse amide-based local anesthetics into the wound to maintain a certain therapeutic concentration. However, this device still has certain drawbacks, such as: the storage bag must be carried at all times, which is inconvenient for patients; the infiltration catheter placed inside the body increases local irritation and poses certain complications; and the infiltration catheter is difficult to remove after treatment. Therefore, the development of long-acting local anesthetics has become a hot research topic.

[0003] Ropivacaine, as one of the safest peripheral nerve block anesthetics on the market, is widely used for acute pain management. Its mechanism of action is to inhibit sodium ion channels in nerve cells, blocking nerve excitation and conduction to achieve anesthesia. Due to its low solubility in water, ropivacaine hydrochloride injection is currently widely used in the market. This injection is available in strengths such as 20mg / 10ml, 50mg / 10ml, 75mg / 10ml, and 100mg / 10ml, all of which are clear, transparent, and free of sediment. A single intrathecal injection provides analgesia for 3-6 hours; however, postoperative pain management requires several days. Clinically, continuous postoperative analgesia for several days can be achieved through non-continuous multiple injections of local anesthetics, or continuous infusion of drugs via epidural or peripheral nerve catheters. Continuous local anesthetic infusion can effectively control pain, but it requires relatively expensive equipment and continuous monitoring, and long-term indwelling catheters can easily cause catheter displacement and complications (such as local tissue necrosis, cellulitis, and surgical wound infection). In addition, frequent administration can increase fluctuations in blood drug concentration, reduce patient compliance, cause pain and inconvenience to patients, and lead to serious side effects.

[0004] Two clinical trial applications for the Class 2 new drug, ropivacaine hydrochloride liposome suspension injection (“LY09606”), have been formally accepted by the Center for Drug Evaluation of the National Medical Products Administration of China. Liposomes, as drug carriers, have good biocompatibility, can controllably release drugs, improve efficacy, and reduce side effects. However, the high price of phospholipids, the excipient for liposomes, and the expensive production equipment keep the production cost of liposomes high. Furthermore, the quality control of liposome formulations is difficult, and the production process is relatively complex, all of which limit the industrialization of liposomes.

[0005] Current research directions for sustained-release formulations of local anesthetics both domestically and internationally include sustained-release local anesthetic surgical sutures, sustained-release local anesthetic in-situ gels, sustained-release local anesthetic fat emulsions, sustained-release local anesthetic liposomes, and sustained-release local anesthetic microspheres (spherical entities formed by embedding drugs in a polymer matrix). There are no reports on the formulation of local anesthetics into aqueous suspensions for injection or powder formulations. Summary of the Invention

[0006] According to one embodiment of this disclosure, a method for preparing ropivacaine suspension injection can be provided, the method comprising:

[0007] (1) Dissolve ropivacaine hydrochloride in water under dispersion condition 1 to undergo an acid-base reaction until pH > 7.5, to obtain mixture 1;

[0008] (2) Add pharmaceutically acceptable excipients to the mixture 1 to obtain mixture 2;

[0009] (3) The mixture 2 is treated under dispersion condition 2.

[0010] According to one embodiment of this disclosure, a ropivacaine suspension injection obtained by the method according to this disclosure can be provided.

[0011] According to one embodiment of this disclosure, polysorbate 80 can be provided as a surfactant in a method for preparing ropivacaine suspension for injection.

[0012] According to one embodiment of this disclosure, a method for preparing ropivacaine powder formulation can be provided, the method comprising:

[0013] (1) Dissolve ropivacaine hydrochloride in water under dispersion condition 1 to undergo an acid-base reaction until pH > 7.5, to obtain mixture 1;

[0014] (2) Add pharmaceutically acceptable excipients to the mixture 1 to obtain mixture 2;

[0015] (3) The mixture 2 is treated under dispersion condition 2;

[0016] (4) Perform freeze-drying treatment.

[0017] According to one embodiment of this disclosure, a ropivacaine powder formulation obtained by the method according to this disclosure can be provided.

[0018] According to one embodiment of this disclosure, polysorbate 80 can be provided as a surfactant in a method for preparing ropivacaine powder formulations. Attached Figure Description

[0019] The following is a brief description of the accompanying drawings, which are used to illustrate the exemplary embodiments disclosed herein and are not intended to limit those embodiments.

[0020] Figure 1 The microstructure of sample II of ropivacaine suspension injection is shown.

[0021] Figure 2 The microstructure of sample VIII of ropivacaine suspension injection is shown.

[0022] Figure 3 The microstructure of sample IX of ropivacaine suspension injection is shown. Detailed Implementation

[0023] Unless otherwise stated, all figures used in this specification and claims to indicate content, concentration, proportion, weight, volume, rotational speed, pressure, particle size, percentage, technical effect, etc., shall in any instance be understood to be modified by the terms “about” or “approximately”. “About” represents a range of ±10% of the value it modifies.

[0024] Therefore, unless otherwise indicated, the numerical parameters listed in the following description and appended claims are approximate values. Unless otherwise stated, the terminology used herein has its common meaning as understood by one of ordinary skill in the art. It will be apparent to those skilled in the art that it may vary depending on the desired properties and effects sought through this disclosure, and each numerical parameter should be interpreted according to the number of significant figures and conventional rounding methods or as understood by one of ordinary skill in the art.

[0025] Although the numerical ranges and parameters described in this disclosure are approximate, the values ​​presented in the specific embodiments are provided as precisely as possible. However, any numerical value will inherently contain some errors, which are necessarily caused by the standard deviation found in its corresponding test measurements. Each numerical range given in this specification will include every narrower numerical range falling within that wider range, as if these narrower numerical ranges were explicitly stated herein.

[0026] Ropivacaine (CAS No.: 84057-95-4) has low solubility in water, while ropivacaine hydrochloride (CAS No.: 132112-35-7) is readily soluble in water, thus an aqueous solution of ropivacaine hydrochloride can be prepared. However, as mentioned above, the sustained-release effect of the injection obtained by dissolving ropivacaine hydrochloride in water is poor and cannot meet clinical needs. Although ropivacaine hydrochloride liposome suspension injection is expected to achieve a sustained-release effect, its high cost, difficulty in quality control, and complex production process make industrialization difficult. In this case, preparing ropivacaine into a suspension injection becomes an alternative. Suspension injections refer to a class of drugs for intramuscular, subcutaneous, or intravenous injection formed by dispersing poorly soluble solid drugs in a liquid dispersion medium in a particulate state. They can be used to prepare long-acting sustained-release formulations. However, suspension injections have particularly high requirements for the particle size, stability, and other properties of drug particles. Currently, no ropivacaine suspension injection has been found to be marketed, approved, or in clinical trials. How to formulate ropivacaine, which has low solubility in water, into a suspension injection with appropriate particle size and good stability in water is a technical challenge that urgently needs to be solved but has not yet been overcome in the existing technology.

[0027] For ropivacaine suspension injection, if the particle size is too small, it will lead to rapid release, thus failing to achieve a prolonged sustained-release effect. If the particle size is too large, it will cause uneven dispersion of ropivacaine at the administration site, resulting in excessive accumulation, multiple releases, unstable blood drug concentrations, and also affecting the permeability of the formulation, making clinical administration inconvenient. Therefore, if the particle size of ropivacaine suspension injection changes significantly after a period of storage, it will adversely affect the safety, efficacy, sustained-release effect, and convenience of clinical administration.

[0028] This disclosure provides a method for preparing ropivacaine suspension for injection, which features a simple production process and relatively low-cost raw materials and equipment. Furthermore, the ropivacaine suspension obtained by this method remains stable in particle size even after being stored at room temperature for 6 months.

[0029] This disclosure also provides a method for preparing ropivacaine powder formulations, which involves a simple production process and relatively low-cost raw materials and equipment. During the storage of the ropivacaine powder formulation obtained by the method of this disclosure, the particle size of the resulting ropivacaine suspension injection remains remarkably stable after reconstitution of the powder formulation.

[0030] When used in this document, the term “reconstitute” refers to mixing ropivacaine powder formulation with water at a weight ratio of 23:1000.

[0031] When used in this article, the particle size-related term "stable" means: D10 in the range of about 0.5 μm to about 5 μm, D50 in the range of about 2 μm to about 15 μm, and D90 in the range of about 5 μm to about 20 μm; and the variation of D50 is less than about 2 μm, and the variation of D90 is less than about 5 μm. When the particle size of ropivacaine suspension injection is stable, it can achieve both a long-term sustained-release effect and stable blood drug concentration, and facilitate clinical administration.

[0032] When used in this article, the particle size-related term "particularly stable" means that D10 is in the range of about 0.5 μm to about 5 μm, D50 is in the range of about 2 μm to about 15 μm, and D90 is in the range of about 5 μm to about 20 μm; and the variation range of D10, D50, and D90 is all less than 1 μm. When the particle size of the suspension obtained after reconstitution of ropivacaine powder formulation is particularly stable, it is possible to further achieve long-term sustained release, stable blood drug concentration, and facilitate clinical administration.

[0033] When used in this document, the term “median particle size D50” or “D50” refers to the particle size at which the cumulative distribution of particles is 50%, that is, the volume content of particles smaller than this size accounts for 50% of all particles.

[0034] When used in this document, the term "D10" refers to the particle size at which the cumulative particle distribution is 10%, meaning that particles smaller than this size account for 10% of the total volume of all particles.

[0035] When used in this document, the term “D90” refers to the particle size at which the cumulative distribution of particles is 90%, meaning that particles smaller than this size account for 90% of the total volume of all particles.

[0036] When used in this article, the term "acid-base reaction" refers to the process in which ropivacaine hydrochloride reacts with an alkaline solution to ultimately produce ropivacaine.

[0037] According to one embodiment of this disclosure, a method for preparing ropivacaine suspension injection can be provided, the method comprising:

[0038] (1) Dissolve ropivacaine hydrochloride in water under dispersion condition 1 to undergo an acid-base reaction until pH > 7.5, to obtain mixture 1;

[0039] (2) Add pharmaceutically acceptable excipients to the mixture 1 to obtain mixture 2;

[0040] (3) The mixture 2 is treated under dispersion condition 2.

[0041] In some embodiments of this disclosure, in step (1), dispersion condition 1 can be: shearing or stirring at a rotational speed of 400-10000 rpm. In some embodiments of this disclosure, in step (1), dispersion condition 1 can be: shearing or stirring at a rotational speed of approximately 600-8000 rpm. In some embodiments of this disclosure, in step (1), dispersion condition 1 can be: shearing or stirring at a rotational speed of approximately 600-5000 rpm.

[0042] In some embodiments of this disclosure, in step (1), a pH adjuster can be added to induce an acid-base reaction in ropivacaine hydrochloride. In some embodiments of this disclosure, the pH adjuster may be selected from one or more of calcium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, monosodium fumarate, sodium citrate, potassium citrate, monosodium citrate, phosphate, calcium sulfate, calcium lactate, sodium acetate, sodium dihydrogen phosphate, and disodium hydrogen phosphate. In some embodiments of this disclosure, the pH adjuster may be sodium hydroxide.

[0043] In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.5 < pH ≤ 11. In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.5 < pH ≤ 10. In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.5 < pH ≤ 9.5. In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.5 < pH ≤ 8.5. In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.7 < pH ≤ 8.3. In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.9 < pH ≤ 8.2. In some embodiments of this disclosure, in step (1), the pH can be adjusted to 7.9 < pH ≤ 8.1.

[0044] In some embodiments of this disclosure, in step (2), pharmaceutically acceptable excipients include suspending agents, surfactants, and optionally isotonic modifiers.

[0045] In some embodiments of this disclosure, the surfactant may be polysorbate 80. Using polysorbate 80 as the surfactant in the methods of this disclosure results in ropivacaine suspension injections with significantly better particle size stability compared to the use of other types of surfactants (e.g., polyethylene glycol 15-hydroxystearate or poloxamer 188), particularly when stored at room temperature for 6 months, during which the particle size of ropivacaine remains stable.

[0046] In some embodiments of this disclosure, approximately 0.1-100 g of polysorbate 80 may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 0.5-10 g of polysorbate 80 may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 0.5-5 g of polysorbate 80 may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 0.55-5 g of polysorbate 80 may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 1-5 g of polysorbate 80 may be added per kilogram of ropivacaine suspension injection in step (2).

[0047] In some embodiments of this disclosure, the suspending agent may be selected from one or more of carboxymethyl cellulose and its sodium salt, hydroxypropyl cellulose and its sodium salt, hydroxypropyl methyl cellulose and its sodium salt, methyl cellulose and its sodium salt, hydroxyethyl cellulose and its sodium salt, sodium hyaluronate, and polyvinylpyrrolidone. In some embodiments of this disclosure, the suspending agent may be sodium carboxymethyl cellulose.

[0048] In some embodiments of this disclosure, approximately 1-20 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 2-10 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 4-10 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 5-9 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 5-8.5 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 5-8.3 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 4-8 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 5 g of suspending agent may be added per kilogram of ropivacaine suspension injection in step (2).

[0049] In some embodiments of this disclosure, the isotonic regulator may be selected from one or more of sodium chloride, mannitol, sorbitol, glucose, sucrose, fructose, and lactose. In some embodiments of this disclosure, the isotonic regulator may be sodium chloride and / or mannitol. In some embodiments of this disclosure, the isotonic regulator may be sodium chloride. In some embodiments of this disclosure, the isotonic regulator may be mannitol.

[0050] In some embodiments of this disclosure, approximately 1-100 g of isotonic adjuster may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 2-50 g of isotonic adjuster may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 4-20 g of sodium chloride may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 4-10 g of sodium chloride may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 4-6 g of sodium chloride may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 4.8 g of sodium chloride may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 10-50 g of mannitol may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 20-40 g of mannitol may be added per kilogram of ropivacaine suspension injection in step (2). In some embodiments of this disclosure, approximately 20-35 g of mannitol may be added per kilogram of ropivacaine suspension injection in step (2).

[0051] In some embodiments of this disclosure, in step (3), the dispersion condition 2 can be: shearing at a rotational speed of approximately 1000-10000 rpm. In some embodiments of this disclosure, in step (3), the dispersion condition 2 can be: shearing at a rotational speed of approximately 2700-10000 rpm. In some embodiments of this disclosure, in step (3), the dispersion condition 2 can be: shearing at a rotational speed of approximately 5000-10000 rpm. In some embodiments of this disclosure, in step (3), the dispersion condition 2 can be: shearing at a rotational speed of approximately 8000-10000 rpm.

[0052] In some embodiments of this disclosure, in step (3), dispersion condition 2 lasts for 10 minutes or longer. In some embodiments of this disclosure, in step (3), dispersion condition 2 lasts for 15 minutes or longer. In some embodiments of this disclosure, in step (3), dispersion condition 2 lasts for 20 minutes or longer. In some embodiments of this disclosure, in step (3), dispersion condition 2 lasts for 60 minutes or longer.

[0053] In some embodiments of this disclosure, each kilogram of the ropivacaine suspension injection may contain about 1-200 g of ropivacaine hydrochloride equivalent. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain about 10-100 g of ropivacaine hydrochloride equivalent. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain about 10-70 g of ropivacaine hydrochloride equivalent. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain about 10-40 g of ropivacaine hydrochloride equivalent. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain about 20-40 g of ropivacaine hydrochloride equivalent. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain approximately 22.8-38 g of ropivacaine hydrochloride equivalent ropivacaine. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain approximately 20-30 g of ropivacaine hydrochloride equivalent ropivacaine. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain approximately 20-25 g of ropivacaine hydrochloride equivalent ropivacaine. According to one embodiment of this disclosure, each kilogram of the ropivacaine suspension injection may contain approximately 22.8 g of ropivacaine hydrochloride equivalent ropivacaine.

[0054] In some embodiments of this disclosure, the D10 of the ropivacaine suspension for injection ranges from about 0.5 μm to about 5 μm, the D50 ranges from about 2 μm to about 15 μm, and the D90 particle size ranges from about 5 μm to about 20 μm. In some embodiments of this disclosure, the D10 of the ropivacaine suspension for injection ranges from about 0.5 μm to about 3 μm, the D50 ranges from about 2 μm to about 10 μm, and the D90 particle size ranges from about 5 μm to about 20 μm. In some embodiments of this disclosure, the D10 of the ropivacaine suspension for injection ranges from about 0.5 μm to about 2 μm, the D50 ranges from about 2 μm to about 8 μm, and the D90 particle size ranges from about 5 μm to about 20 μm. In some embodiments of this disclosure, the D10 of the ropivacaine suspension injection ranges from about 0.5 μm to about 2 μm, the D50 ranges from about 2 μm to about 8 μm, and the D90 particle size ranges from about 5 μm to about 17 μm.

[0055] In some embodiments of this disclosure, the D50 of the ropivacaine suspension injection changes by less than about 2 μm and the D90 changes by less than about 5 μm during a 6-month period at room temperature.

[0056] In some embodiments of this disclosure, the pH of the ropivacaine suspension for injection is about 7-9. In some embodiments of this disclosure, the pH of the ropivacaine suspension for injection is about 7.5-8.8. In some embodiments of this disclosure, the pH of the ropivacaine suspension for injection is about 7.7-8.6. In some embodiments of this disclosure, the pH of the ropivacaine suspension for injection is about 7.7-8.3. In some embodiments of this disclosure, the pH of the ropivacaine suspension for injection is about 7.7-8.

[0057] The various embodiments and preferred options described above with respect to the method for preparing ropivacaine suspension injection of this disclosure can be combined with each other (as long as they are not inherently contradictory to each other), and all embodiments formed by such combinations are considered as part of this disclosure.

[0058] According to one embodiment of the present disclosure, a ropivacaine suspension injection obtained by the method of the present disclosure can be provided.

[0059] In some embodiments of this disclosure, the ropivacaine suspension injection of this disclosure, when stored at room temperature for 6 months, has a D10 in the range of about 0.5 μm to about 5 μm, a D50 in the range of about 2 μm to about 15 μm, and a D90 particle size in the range of about 5 μm to about 20 μm; and the variation range of D50 is less than about 2 μm, and the variation range of D90 is less than about 5 μm.

[0060] According to one embodiment of this disclosure, polysorbate 80 can be provided as a surfactant in a method for preparing ropivacaine suspension for injection.

[0061] The various embodiments and preferences described above for the method of preparing ropivacaine suspension injection of this disclosure are also applicable to the ropivacaine suspension injection and uses of this disclosure. These embodiments and preferences can also be combined with each other (as long as they are not inherently contradictory to each other), and the various embodiments formed by such combinations are considered as part of this application disclosure.

[0062] According to one embodiment of this disclosure, a method for preparing ropivacaine powder formulation can be provided, the method comprising:

[0063] (1) Dissolve ropivacaine hydrochloride in water under dispersion condition 1 to undergo an acid-base reaction until pH > 7.5, to obtain mixture 1;

[0064] (2) Add pharmaceutically acceptable excipients to the mixture 1 to obtain mixture 2;

[0065] (3) The mixture 2 is treated under dispersion condition 2;

[0066] (4) Perform freeze-drying treatment.

[0067] In some embodiments of this disclosure, the "freeze-drying process" includes four stages: a pre-freezing stage, a first drying stage 1, a first drying stage 2, and a second drying stage 1.

[0068] In some embodiments of this disclosure, pre-freezing refers to maintaining a temperature of approximately -45.0°C for approximately 90-120 minutes. In some embodiments of this disclosure, pre-freezing refers to maintaining a temperature of approximately -45.0°C for approximately 90 minutes. In some embodiments of this disclosure, the cooling time during the pre-freezing stage is approximately 1-60 minutes. In some embodiments of this disclosure, the cooling time during the pre-freezing stage is approximately 1 minute. In some embodiments of this disclosure, the cooling time during the pre-freezing stage is approximately 60 minutes.

[0069] In some embodiments of this disclosure, the first drying stage refers to a drying process lasting approximately 900-1200 minutes at a temperature of approximately -5.0°C and a vacuum of approximately 250-300 μbar. In some embodiments of this disclosure, the first drying stage refers to a drying process lasting approximately 900 minutes at a temperature of approximately -5.0°C and a vacuum of approximately 300 μbar. In some embodiments of this disclosure, the heating time in the first drying stage is approximately 60-90 minutes. In some embodiments of this disclosure, the heating time in the first drying stage is approximately 60 minutes.

[0070] In some embodiments of this disclosure, the second drying stage refers to a drying process lasting approximately 60-240 minutes at a temperature of approximately 5.0°C and a vacuum of approximately 250-300 μbar. In some embodiments of this disclosure, the second drying stage refers to a drying process lasting approximately 60-120 minutes at a temperature of approximately 5.0°C and a vacuum of approximately 300 μbar. In some embodiments of this disclosure, the second drying stage refers to a drying process lasting approximately 60 minutes at a temperature of approximately 5.0°C and a vacuum of approximately 300 μbar. In some embodiments of this disclosure, the second drying stage refers to a drying process lasting approximately 120 minutes at a temperature of approximately 5.0°C and a vacuum of approximately 300 μbar. In some embodiments of this disclosure, the heating time in the second drying stage is approximately 30-60 minutes. In some embodiments of this disclosure, the heating time in the second drying stage is approximately 30 minutes.

[0071] In some embodiments of this disclosure, the first stage of secondary drying refers to a process lasting approximately 60-240 minutes at a temperature of approximately 35.0°C and a vacuum of approximately 1.0 μbar. In some embodiments of this disclosure, the first stage of secondary drying refers to a process lasting approximately 60 minutes at a temperature of approximately 35.0°C and a vacuum of approximately 1.0 μbar. In some embodiments of this disclosure, the heating time in the first stage of secondary drying is approximately 40-90 minutes. In some embodiments of this disclosure, the heating time in the first stage of secondary drying is approximately 40-60 minutes. In some embodiments of this disclosure, the heating time in the first stage of secondary drying is approximately 40 minutes. In some embodiments of this disclosure, the heating time in the first stage of secondary drying is approximately 60 minutes.

[0072] In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension has a D10 in the range of 0.5 μm to 5 μm, a D50 in the range of 2 μm to 15 μm, and a D90 in the range of 5 μm to 20 μm. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension has a D10 in the range of about 0.5 μm to about 3 μm, a D50 in the range of about 2 μm to about 10 μm, and a D90 particle size in the range of about 5 μm to about 20 μm. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension has a D10 in the range of about 0.5 μm to about 2 μm, a D50 in the range of about 2 μm to about 8 μm, and a D90 particle size in the range of about 5 μm to about 20 μm. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension has a D10 in the range of about 0.5 μm to about 2 μm, a D50 in the range of about 2 μm to about 8 μm, and a D90 particle size in the range of about 5 μm to about 17 μm. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension has a D10 ranging from about 0.5 μm to about 1.5 μm, a D50 ranging from about 3 μm to about 8 μm, and a D90 particle size ranging from about 8 μm to about 16 μm. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension has a D10 ranging from about 1 μm to about 1.5 μm, a D50 ranging from about 4 μm to about 7 μm, and a D90 particle size ranging from about 10 μm to about 15 μm.

[0073] In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension contains 0.1 g to 0.9 g of ropivacaine hydrochloride equivalent ropivacaine. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension contains 0.2 g to 0.8 g of ropivacaine hydrochloride equivalent ropivacaine. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension contains 0.3 g to 0.7 g of ropivacaine hydrochloride equivalent ropivacaine. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension contains 0.4 g to 0.6 g of ropivacaine hydrochloride equivalent ropivacaine. In some embodiments of this disclosure, when each gram of the ropivacaine powder formulation is mixed with water at a weight ratio of 23:1000, the resulting ropivacaine suspension contains 0.5 g to 0.6 g of ropivacaine hydrochloride equivalent ropivacaine.

[0074] According to one embodiment of this disclosure, a ropivacaine powder formulation obtained by the method according to this disclosure can be provided.

[0075] According to one embodiment of this disclosure, polysorbate 80 can be provided as a surfactant in a method for preparing ropivacaine powder formulations.

[0076] The various embodiments and preferences described above regarding the method for preparing ropivacaine suspension injection, the ropivacaine suspension injection, and its uses are also applicable to the method for preparing ropivacaine powder formulation, the ropivacaine powder formulation, and its uses. These embodiments and preferences can also be combined with each other (as long as they are not inherently contradictory), and all embodiments formed by such combinations are considered part of this application disclosure.

[0077] The technical solutions of this disclosure will be illustrated more clearly and explicitly below with reference to embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of protection of this disclosure. The scope of protection of this disclosure is defined only by the claims.

[0078] Example

[0079] Ropivacaine hydrochloride used in Examples 1-9 was purchased from Xianju Pharmaceutical Co., Ltd.; ropivacaine hydrochloride used in Examples 10-12 was purchased from Qingdao Jinfeng Pharmaceutical Co., Ltd.; sodium carboxymethyl cellulose was purchased from Ashland; poloxamer 188 was purchased from Merck; polysorbate 80 was purchased from Nanjing Weier Pharmaceutical Co., Ltd.; polyethylene glycol 15-hydroxystearate was purchased from Beijing Fengli Jingqiu Pharmaceutical Co., Ltd.; sodium chloride was purchased from Jiangsu Qinfen Pharmaceutical Co., Ltd.; and sodium hydroxide was purchased from Nanjing Chemical Reagent Co., Ltd. Unless otherwise stated, the reaction temperature for each step was room temperature, and the pressure was atmospheric pressure. In each example, the particle size of the suspension was measured using a NeoPatek laser particle size analyzer, model HELOs, manufactured by NeoPatek GmbH, Germany; and the microstructure of the samples was observed using a Malvern static particle size, shape, and chemical composition analyzer, model Morphologi4-ID, manufactured by Malvern Panaco.

[0080] Example 1 Preparation of Ropivacaine Suspension for Injection I

[0081] Weigh 2.28g of ropivacaine hydrochloride (white or off-white crystals or crystalline powder) and dissolve it in 75% of the total prepared solution volume of water. Slowly add 0.5M sodium hydroxide solution for alkaline precipitation, while simultaneously using magnetic stirring at 600rpm to adjust the pH to 7.98. Add 0.5g of polysorbate 80 and 0.5g of sodium carboxymethyl cellulose, and use high shear at 8000rpm for 20min to fully disperse the mixture. Make up the volume to 100g with ultrapure water. The pH of the solution after volume adjustment is 7.76. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding particle sizes D10: 1.28μm, D50: 5.90μm, and D90: 14.02μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0082] Table 1: Particle size change of Ropivacaine Suspension Injection I when placed at room temperature

[0083]

[0084]

[0085] Example 2 Preparation of Ropivacaine Suspension for Injection II

[0086] 4.56 g of ropivacaine hydrochloride was dissolved in 75% water of the total prepared solution. A 1M sodium hydroxide solution was slowly added for alkali precipitation, while magnetic stirring at 750 rpm was used to adjust the pH to 8.04. 0.6 g of polysorbate 80 and 1.0 g of sodium carboxymethyl cellulose were added, and the mixture was thoroughly dispersed by high shear at 8000 rpm for 15 minutes. The volume was then adjusted to 200 g with ultrapure water. The pH of the final solution was 7.91. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding D10: 1.05 μm, D50: 4.06 μm, and D90: 10.29 μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0087] Table 2: Particle size change of Ropivacaine Suspension Injection II when stored at room temperature

[0088] Particle size D10 / μm D50 / μm D90 / μm 0 days 1.05 4.06 10.29 15 days at room temperature 0.94 3.05 8.66 30 days at room temperature 0.94 3.11 8.66 Normal temperature March 0.93 2.93 7.44 Room temperature June 1.00 3.29 9.39

[0089] The microstructure of the sample was observed using a Malvern static particle size, shape, and chemical composition analyzer, revealing it to be a granular crystal. The results are as follows: Figure 1 As shown.

[0090] Example 3 Preparation of Ropivacaine Suspension for Injection III

[0091] 2.28 g of ropivacaine hydrochloride was dissolved in 70% of the total solution volume of water. A 1M sodium hydroxide solution was slowly added for alkali precipitation, while simultaneously using a high-shear rotation speed of 5000 rpm to ensure uniform mixing. The pH was adjusted to 8.0. 0.28 g of polysorbate 80, 0.48 g of sodium chloride, and 0.5 g of sodium carboxymethyl cellulose were added, and the mixture was thoroughly dispersed using a high-shear rotation speed of 10000 rpm for 20 minutes. The volume was then adjusted to 100 g with ultrapure water. The pH of the final solution was 7.90. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding particle sizes D10: 1.22 μm, D50: 4.67 μm, and D90: 10.69 μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0092] Table 3: Particle size change of Ropivacaine Suspension Injection III when stored at room temperature

[0093]

[0094]

[0095] Example 4 Preparation of Ropivacaine Suspension for Injection IV

[0096] 2.28 g of ropivacaine hydrochloride was dissolved in 75% water of the total prepared solution. A 1M sodium hydroxide solution was slowly added for alkali precipitation, while the solution was magnetically stirred at 600 rpm to adjust the pH to 8.02. 0.25 g of polysorbate 80 and 0.5 g of sodium carboxymethyl cellulose were added, and the mixture was thoroughly dispersed by high shear at 8000 rpm for 20 minutes. The volume was then adjusted to 100 g with ultrapure water. The pH of the final solution was 7.82. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding D10: 1.19 μm, D50: 4.70 μm, and D90: 10.18 μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0097] Table 4: Particle size change of Ropivacaine suspension IV at room temperature

[0098] Particle size D10 / μm D50 / μm D90 / μm 0 days 1.19 4.70 10.18 7 days at room temperature 1.12 4.73 12.40 30 days at room temperature 1.12 4.72 11.87 Normal temperature March 1.09 4.56 10.09 Room temperature June 1.23 5.94 14.53

[0099] Example 5 Preparation of Ropivacaine Suspension for Injection V

[0100] 2.28 g of ropivacaine hydrochloride was dissolved in 75% water of the total prepared solution. A 0.5 M sodium hydroxide solution was slowly added for alkali precipitation, while simultaneously using magnetic stirring at 900 rpm to adjust the pH to 8.02. 0.1 g of polysorbate 80 and 0.5 g of sodium carboxymethyl cellulose were added, and the mixture was thoroughly dispersed using high shear at 8000 rpm for 20 minutes. The volume was then adjusted to 100 g with ultrapure water. The pH of the final solution was 7.91. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding D10: 1.14 μm, D50: 4.43 μm, and D90: 9.96 μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0101] Table 5: Particle size change of ropivacaine suspension injection at room temperature (V)

[0102] Particle size D10 / μm D50 / μm D90 / μm 0 days 1.14 4.43 9.96 14 days at room temperature 0.99 3.55 9.56 30 days at room temperature 1.02 4.17 12.30 Normal temperature March 1.13 4.97 12.94 Room temperature June 1.21 5.70 12.95

[0103] Comparative Examples 6 Preparation of Ropivacaine Suspension for Injection VI

[0104] 2.28 g of ropivacaine hydrochloride was dissolved in 75% water of the total prepared solution. A 1M sodium hydroxide solution was slowly added for alkali precipitation, while the solution was magnetically stirred at 600 rpm to adjust the pH to 8.19. 0.5 g of polyethylene glycol 15-hydroxystearate and 0.5 g of sodium carboxymethyl cellulose were added, and the mixture was thoroughly dispersed by high shear at 8000 rpm for 20 minutes. The volume was then adjusted to 100 g with ultrapure water. The pH of the final solution was 7.85. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding D10: 1.53 μm, D50: 7.60 μm, and D90: 19.83 μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0105] Table 6: Particle size change of Ropivacaine suspension injection VI at room temperature

[0106] Particle size D10 / μm D50 / μm D90 / μm 0 days 1.53 7.60 19.83 18 days at room temperature 1.51 7.67 36.16 30 days at room temperature 1.45 7.64 33.47 Normal temperature March 2.66 15.04 75.33

[0107] Comparative Examples 7 Preparation of Ropivacaine Suspension for Injection VII

[0108] 2.28 g of ropivacaine hydrochloride was dissolved in 75% water of the total prepared solution. A 1M sodium hydroxide solution was slowly added for alkali precipitation, while the solution was magnetically stirred at 600 rpm to adjust the pH to 7.96. 0.5 g of poloxamer 188 and 0.5 g of sodium carboxymethyl cellulose were added, and the mixture was thoroughly dispersed by high shear at 8000 rpm for 20 minutes. The volume was then adjusted to 100 g with ultrapure water. The pH of the final solution was 7.78. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding D10: 6.51 μm, D50: 17.39 μm, and D90: 32.94 μm. Samples were taken and the particle size of the suspension at room temperature was measured; details are shown in the table below.

[0109] Table 7: Particle size change of Ropivacaine Suspension Injection VII at room temperature

[0110] Particle size D10 / μm D50 / μm D90 / μm 0 days 6.51 17.39 32.94 18 days at room temperature 8.14 24.13 44.44 30 days at room temperature 6.98 21.44 39.24 Normal temperature March 2.36 14.05 33.79

[0111] The results of Examples 1-5 and Comparative Examples 6-7 show that: During 6 months of storage at room temperature, the particle size distribution of ropivacaine suspension IV was approximately 0.5 μm to 5 μm, D50 was approximately 2 μm to 15 μm, and D90 was approximately 5 μm to 20 μm, with D50 variation less than 2 μm and D90 variation less than 5 μm. However, during 3 months of storage at room temperature, the particle sizes of ropivacaine suspensions VI and VII showed significant increases in D50 or D90, with D50 variation greater than 7 μm and / or D90 variation greater than 10 μm, and / or D50 greater than 15 μm and / or D90 greater than 30 μm. This indicates that, under the same preparation process, the particle size stability of the formulation using polysorbate 80 surfactant is significantly better than that of the formulation using poloxamer 188 or polyethylene glycol 15-hydroxystearate surfactant.

[0112] Comparative Examples 8 Preparation of Ropivacaine Suspension for Injection VIII

[0113] 0.5 g of sodium carboxymethyl cellulose and 2.28 g of ropivacaine hydrochloride were dissolved in 75% water, and the mixture was thoroughly dispersed using a high-shear method at 8000 rpm. A 1M sodium hydroxide solution was slowly added for alkali precipitation, while the solution was magnetically stirred at 1000 rpm to adjust the pH to 8.0. 0.28 g of polysorbate 80 and 0.48 g of sodium chloride were added, and the mixture was thoroughly dispersed using a high-shear method at 8000 rpm for 20 minutes. The volume was then adjusted to 100 g with ultrapure water, resulting in a final pH of 8.04. The particle size of the suspension was measured using a Neopatek laser particle size analyzer, yielding D10: 0.95 μm, D50: 3.54 μm, and D90: 8.78 μm. The microstructure of the sample was observed using a Malvern static particle size, shape, and chemical composition analyzer, showing granular crystals. The results are as follows. Figure 2 As shown.

[0114] The particle size of the suspension was sampled and measured at room temperature, as detailed in the table below:

[0115] Table 8: Particle size change of Ropivacaine Suspension VIII when stored at room temperature

[0116] Particle size D10 / μm D50 / μm D90 / μm 0 days 0.95 3.54 8.78 7 days at room temperature 1.25 4.62 13.77 February at normal temperature 1.28 4.75 14.64 Normal temperature March 1.36 5.09 16.36 Room temperature June 1.38 5.16 17.18

[0117] Compared to ropivacaine suspension injections I-VI, ropivacaine suspension injection VIII exhibited significantly worse stability, with particle size D90 increasing by more than 8 μm over 6 months, while the particle size D90 of ropivacaine suspension injections I-VI increased by no more than 5 μm over the same period. Furthermore, during 6 months of storage at room temperature, the D10, D50, and D90 values ​​of ropivacaine suspension injection VIII all showed a gradual increasing trend over time, thus it is reasonable to expect continued increases with prolonged storage.

[0118] The results of Examples 1-5 and Comparative Example 8 show that, for the method of preparing ropivacaine suspension injection of the present invention, changing the timing of the addition of pharmaceutically acceptable excipients (specifically suspending agents, more specifically sodium carboxymethyl cellulose) under the same formulation results in a significant decrease in the stability of the resulting ropivacaine suspension injection.

[0119] Comparative Examples 9 Preparation of Ropivacaine Suspension for Injection IX

[0120] 1.0 g of sodium carboxymethyl cellulose, 4.56 g of ropivacaine hydrochloride, and 0.60 g of polysorbate 80 were weighed and dissolved in 75% water. The solution was thoroughly dispersed using a high-shear method at 8000 rpm. Then, 1 M sodium hydroxide solution was slowly added for alkaline precipitation, while magnetic stirring was performed at 750 rpm to adjust the pH to 8.20. The mixture was then thoroughly dispersed using a high-shear method at 8000 rpm for 15 minutes. The volume was adjusted to 200 g with ultrapure water, resulting in a final pH of 8.23. The particle size distribution of the suspension was determined using a Neopatek laser particle size analyzer, yielding D10: 1.71 μm, D50: 8.80 μm, and D90: 49.71 μm. The microstructure of the sample was observed using a Malvern static particle size distribution and chemical composition analyzer, showing needle-like crystals of varying lengths, indicating a wide particle size distribution. The results are as follows: Figure 3 As shown.

[0121] By comparing the microstructure of the samples from Example 2 and Comparative Example 9, it was demonstrated that, for the method of preparing ropivacaine suspension injection of the present invention, changing the timing of the addition of pharmaceutically acceptable excipients (specifically suspending agents and surfactants, more specifically sodium carboxymethyl cellulose and polysorbate 80) under the same formulation resulted in poor particle size and particle size distribution of the ropivacaine suspension injection, which could not be used as a drug.

[0122] Example 10 Preparation of Ropivacaine Powder Formulation X

[0123] 9.12 g of ropivacaine hydrochloride was weighed and dissolved in water. The mixture was sheared at 8000 rpm, and 2M sodium hydroxide solution was slowly added for alkaline precipitation. The pH was adjusted to 8.0. 0.2 g of polysorbate 80, 2.0 g of sodium carboxymethyl cellulose, and 8 g of mannitol were weighed, dissolved in water, and mixed with the alkaline-precipitated active pharmaceutical ingredient. The mixture was sheared at 8000 rpm for 15 min to ensure thorough dispersion. The volume was adjusted to 240 g with ultrapure water. The pH of the resulting suspension was 8.60. After freeze-drying, the product was a white, loose cake. 0.23 g of the freeze-dried product was taken, and 10 ml of water was added with gentle shaking. The product reconstituted in less than 3 min. The resulting ropivacaine suspension contained the equivalent of 120 mg of ropivacaine hydrochloride. The particle size was measured after reconstitution. The particle sizes were D10: 1.21 μm, D50: 4.99 μm, and D90: 10.69 μm. The freeze-drying process parameters are shown in Table 9.

[0124] Table 9: Freeze-drying process parameters

[0125] freeze-drying stage Set temperature / °C Heating (cooling) time / min Duration / min Set vacuum level / μbar Pre-freezing -45.0 60 90 / First drying stage 1 -5.0 60 900 300 First drying stage 2 5.0 30 60 300 Secondary drying stage 1 35.0 60 60 1.0

[0126] The particle size of the freeze-dried product after reconstitution at room temperature was sampled and tested, as detailed in Table 10 below:

[0127] Table 10: Particle size change of ropivacaine powder formulation after being left at room temperature

[0128] Particle size D10 / μm D50 / μm D90 / μm 0 days 1.21 4.99 10.69 3 months at room temperature 1.21 5.39 11.09

[0129] Example 11 Preparation of Ropivacaine Powder Formulation XI

[0130] The following process was carried out using pilot-scale production equipment. 960g of ropivacaine hydrochloride was dissolved in water in a mixing tank. The mixture was sheared at 2700 rpm, and 2M sodium hydroxide solution was slowly added for alkaline precipitation, adjusting the pH to 9.75. 20g of polysorbate 80, 200g of sodium carboxymethyl cellulose, and 800g of mannitol were weighed, dissolved in water, and added to the mixing tank. The mixture was sheared at 2700 rpm for 60 minutes to ensure thorough dispersion. The total volume of the resulting suspension was 29.5 kg, and the pH was 8.52. After freeze-drying, the product was a white, loose cake. 0.23g of the freeze-dried product was taken, and 10ml of water was added with gentle shaking. The product reconstitution time was less than 3 minutes. The resulting ropivacaine suspension contained the equivalent of 120mg of ropivacaine hydrochloride. The particle size was measured after reconstitution. The particle sizes were D10: 1.16 μm, D50: 4.97 μm, and D90: 11.42 μm. The freeze-drying process parameters are shown in Table 11.

[0131] Table 11: Freeze-drying process parameters

[0132] freeze-drying stage Set temperature / °C Heating (cooling) time / min Duration / min Set vacuum level / μbar Pre-freezing -45.0 1 90 / First drying stage 1 -5.0 60 900 300 First drying stage 2 5.0 30 120 300 Secondary drying stage 1 35.0 40 60 1.0

[0133] The particle size of the freeze-dried product after reconstitution at room temperature was sampled and tested, as detailed in Table 12 below:

[0134] Table 12: Particle size change of Ropivacaine powder formulation XI when stored at room temperature

[0135] Particle size D10 / μm D50 / μm D90 / μm 0 days 1.16 4.97 11.42 Room temperature January 1.17 5.09 12.00 February at normal temperature 1.18 5.23 11.91

[0136] The ropivacaine powder formulations prepared in Examples 10 and 11, after reconstitution, exhibited particle sizes ranging from 0.5 μm to 5 μm (D10), 2 μm to 15 μm (D50), and 5 μm to 20 μm (D90). Furthermore, during their respective testing periods, the variations in D10, D50, and D90 after reconstitution were all less than 1 μm. This demonstrates that the particle size of the ropivacaine powder formulation obtained by the method of this disclosure remains remarkably stable during storage, even after reconstitution. Additionally, Example 11 illustrates that large-scale production can be successfully achieved according to the method described in this disclosure.

Claims

1. A method for preparing ropivacaine suspension for injection, comprising: (1) Ropivacaine hydrochloride is dispersed in water under dispersion condition 1, and a pH adjuster is added to cause an acid-base reaction of ropivacaine hydrochloride until pH > 7.5, to obtain mixture 1; (2) Add pharmaceutically acceptable excipients to mixture 1 to obtain mixture 2; (3) The mixture 2 is treated under dispersion condition 2; The pharmaceutically acceptable excipients include surfactants, suspending agents, and optional isotonicity modifiers, wherein the surfactant is polysorbate 80 and the suspending agent is sodium carboxymethyl cellulose. The dispersion condition 1 is: shearing or stirring at a speed of 600-5000 rpm; The dispersion condition 2 is: shearing at a rotation speed of 8000-10000 rpm; The ropivacaine suspension injection has a D10 in the range of 0.5 μm to 5 μm, a D50 in the range of 2 μm to 15 μm, and a D90 particle size in the range of 5 μm to 20 μm.

2. The method of claim 1, wherein the dispersion condition 2 lasts for 10 minutes or longer.

3. The method of claim 2, wherein for each kilogram of the ropivacaine suspension injection, in step (2), 0.1-100 g of polysorbate 80 is added.

4. The method of claim 1, wherein each kilogram of the ropivacaine suspension contains 1-200 g of ropivacaine hydrochloride equivalent ropivacaine.

5. Ropivacaine suspension for injection obtained by the method of any one of claims 1-4.

6. A method for preparing ropivacaine powder formulation, comprising: (1) Ropivacaine hydrochloride is dispersed in water under dispersion condition 1, and a pH adjuster is added to cause an acid-base reaction of ropivacaine hydrochloride until pH > 7.5, to obtain mixture 1; (2) Add pharmaceutically acceptable excipients to mixture 1 to obtain mixture 2; (3) The mixture 2 is treated under dispersion condition 2; (4) Perform freeze-drying treatment; The pharmaceutically acceptable excipients include surfactants, suspending agents, and optional isotonicity modifiers, wherein the surfactant is polysorbate 80 and the suspending agent is sodium carboxymethyl cellulose. The dispersion condition 1 is: shearing or stirring at a speed of 600-5000 rpm; The dispersion condition 2 is: shearing at a rotation speed of 8000-10000 rpm; The ropivacaine suspension injection has a D10 in the range of 0.5 μm to 5 μm, a D50 in the range of 2 μm to 15 μm, and a D90 particle size in the range of 5 μm to 20 μm.

7. The ropivacaine powder formulation obtained by the method of claim 6.

Citation Information

Patent Citations

  • S-(-)-1-propyl-2',6'-aminoxyleneformylpiperidine crystal and sustained release preparation thereof

    WO2017036408A1